Illumina took a bold step in 2021 when it closed the $8 billion acquisition of Grail, maker of a multi-cancer early detection test, before securing the approval of antitrust regulators.
The DNA sequencing leader has been dealing with the fallout of that decision ever since, as regulators in both the U.S. and Europe turned up the heat, and activist shareholder Carl Icahn joined the fray.
Last week, Illumina finally said it would pursue a sale or spinoff of Grail, after more than two years of controversy surrounding the deal.
MedTech Dive has kept readers on top of the dozens of twists and turns in Illumina’s battles with regulators and Icahn. Here is a collection of our coverage of the story in 2023: